In a breakthrough that could help address the growing crisis of antibiotic resistance, researchers at Harvard and MIT have used artificial intelligence to discover a new class of antibiotics that kill bacteria through an entirely novel mechanism.
The compound, called halicin-2, was identified by a deep learning model trained on millions of molecular structures. In laboratory tests, it proved effective against several strains of drug-resistant bacteria, including MRSA and carbapenem-resistant Enterobacteriaceae.
How It Works
Unlike conventional antibiotics, which typically target bacterial cell walls or protein synthesis, halicin-2 disrupts the electrochemical gradient across bacterial cell membranes. This mechanism makes it significantly harder for bacteria to develop resistance.
Clinical Path
The researchers cautioned that extensive testing remains before the drug could reach patients. Clinical trials are expected to begin in early 2027, with the compound first being tested for safety in healthy volunteers.
A New Paradigm
The discovery is part of a broader trend of using AI to accelerate drug development. Pharmaceutical companies are increasingly investing in machine learning platforms that can screen billions of potential drug candidates in a fraction of the time required by traditional methods.
